The myelodysplastic syndromes (also known as MDS or myelodysplasia) are hematological (i.e., blood-related) medical conditions with ineffective production (or "dysplasia") of all blood cells.
Patients with MDS can develop severe anemia and require blood transfusions. In some cases, the disease worsens and the patient develops cytopenias (low blood counts) caused by progressive bone marrow failure. The outlook in MDS depends on the type and severity. Many people live normal lifespans with MDS.
The myelodysplastic syndromes are all disorders of the hematopoietic stem cells in the bone marrow (only related tomyeloid lineage). In MDS, hematopoiesis (i.e., blood production) is disorderly and ineffective. The number and quality of blood-forming cells decline irreversibly, further impairing blood production. The mean age of onset of MDS is 68 years.
We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.
http://www.hindawi.com/journals/ah/2010/164045/ maha a. badawi, linda m. vickars, jocelyn m. chase, and heather a. leitch, “red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome,” advances in hematology, vol. 2010, article id 164045, 5 pages, 2010. doi:10.1155/2010/164045
http://www.hindawi.com/journals/crionm/2016/8308179/ udit bhaskar bhatnagar, daulath singh, alexy glazyrin, and jill moormeier, “paclitaxel induced mds and aml: a case report and literature review,” case reports in oncological medicine, vol. 2016, article id 8308179, 5 pages, 2016. doi:10.1155/2016/8308179